Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
7 results loaded, newest first. End of these results.
The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, a successful postpartum depression launch, and a promising pipeline. The planned Indivior merger aims to accelerate diversification and cash flow, supporting further R&D and M&A.Based on Supernus P…
Indivior and Supernus say they will combine in an all-stock, tax-free merger of equals, with expected annual cost synergies of $125 million.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better se
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) and Indivior Pharmaceuticals Inc. (NASDAQ: INDV ) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmaceutical company. The combined business will operate as Supernus and trade on the Nasdaq Global Market
Supernus and Indivior merge to create CNS biopharmaceutical leader
SUPN INDV Supernus Pharmaceuticals and Indivior Pharmaceuticals to merge, creating a diversified Cns biopharmaceutical leader with significant scale Supernus Pharmaceuticals Inc - combined entity to be named Supernus, Inc. and Jack khattar to serve as President and Chief Executive Officer - Definitive agreement to comb
Supernus and Indivior merge to create CNS biopharmaceutical leader